AKRO
Akero Therapeutics Inc
NASDAQ: AKRO · HEALTHCARE · BIOTECHNOLOGY
$54.65
+0.00% today
Updated 2025-12-09
Market cap
$4.50B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.75
Dividend yield
—
52W range
$32 – $57
Volume
2.9M
Akero Therapeutics Inc (AKRO) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — |
| Cost of revenue | $0.00 | $0.00 | — | $80.15M | $100.89M | $260000.00 | $29000.00 | $18000.00 |
| Gross profit | $0.00 | $0.00 | — | $-80.15M | $-100.89M | $-260000.00 | $-29000.00 | $-18000.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $3.49M | $11.88M | $37.05M | $64.92M | $81.76M | $85.28M | $141.80M | $247.50M |
| SG&A | $1.18M | $1.90M | $8.61M | $15.24M | $19.13M | $29.87M | $31.07M | $37.93M |
| Operating income | $-4.56M | $-13.78M | $-45.65M | $-80.15M | $-100.89M | $-115.16M | $-172.87M | $-285.42M |
| Operating margin | — | — | — | — | — | — | — | — |
| EBITDA | $-232363.00 | $-68.46M | $-45.65M | $-80.14M | $-100.84M | $-111.25M | $-148.63M | $-247.37M |
| EBITDA margin | — | — | — | — | — | — | — | — |
| EBIT | $-5.21M | $-82.23M | $-45.65M | $-80.15M | $-100.89M | $-111.29M | $-148.66M | $-247.39M |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $41000.00 | $739000.00 | $3.10M | $4.67M |
| Income tax | $-4.98M | $-68.10M | $-1.90M | $-17000.00 | $-41000.00 | $-3.12M | — | — |
| Effective tax rate | 52.2% | 45.5% | 4.2% | 0.0% | 0.0% | 2.7% | 0.0% | 0.0% |
| Net income | $-4.56M | $-81.71M | $-43.76M | $-79.19M | $-100.74M | $-112.03M | $-151.76M | $-252.06M |
| Net income growth (YoY) | — | -1690.4% | +46.5% | -81.0% | -27.2% | -11.2% | -35.5% | -66.1% |
| Profit margin | — | — | — | — | — | — | — | — |